Edwards Lifesciences Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Edwards Lifesciences Corporation's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 65.1 times by its yearly operating cash. Higher than 96% of Healthcare companies in United States.
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $46 of operating cash. Lower than 94% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$46Over the last 3 years, every $100 of reported profit came with $46 of operating cash.
Lower than 94% of Healthcare companies in United States.
Self-Funding Ratio
3.7×Over the last 3 years its own operating cash covered its investment spending (capex) 3.7 times.
Higher than 82% of Healthcare companies in United States.
Cash Locked Ratio
$25For every $100 of sales, $25 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $29 tied up three years earlier.
More money tied up than 55% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
−$28Sales grew 36% in 3 years, but profit fell: $28 less profit per $100 of extra sales.
Lower than 78% of Healthcare companies in United States.
Asset Productivity Ratio
+36% / +65%In 3 years sales changed by +36% while total assets changed by +65%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
65.1×Debt due within a year is covered 65.1 times by its yearly operating cash.
Higher than 96% of Healthcare companies in United States.
Cash Cushion Ratio
+7%Cash, after subtracting all debt, equals 7% of its market value (net cash).
Lower than 54% of Healthcare companies in United States.
Tangible Assets Ratio
79%Of every $100 the company owns, $79 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 52% of Healthcare companies in United States.
Tangible Net Worth Ratio
72%Of every $100 of net worth, $72 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 58% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Edwards Lifesciences Corporation owes $0.23 for every $1 it owns. Net profit fell 74% in the year to Dec 2025, and shrank 11% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
53.0Investors pay $53.0 for every $1 of Edwards Lifesciences Corporation's yearly profit, higher than 82% of Healthcare companies in United States.
P/B ratio
4.84The share price is 4.84 times Edwards Lifesciences Corporation's book value per share, higher than 71% of Healthcare companies in United States.
Market cap
$51.3 BThe total market value of all of Edwards Lifesciences Corporation's shares at today's price (share price × number of shares), larger than 97% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$10.6 BWhat Edwards Lifesciences Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$18.42Net worth divided by the number of shares. The share price of $89.07 is 4.8 times this, which is the P/B above.
Return on equity (ROE)
9.2%Edwards Lifesciences Corporation earned 9.2% on its shareholders' money over the last year, higher than 83% of Healthcare companies in United States.
Owes vs Owns
0.23×Edwards Lifesciences Corporation owes $0.23 for every $1 it owns (low), lower than 69% of Healthcare companies in United States.
Dividend yield
NoneEdwards Lifesciences Corporation does not currently pay a dividend.
Revenue growth
+12%Revenue rose 12% in the year to Dec 2025, and grew 11% a year on average over 3 years.
Profit growth
-74%Net profit fell 74% in the year to Dec 2025, and shrank 11% a year on average over 3 years.
Profit margin
17.7%Edwards Lifesciences Corporation keeps $18 of every $100 of revenue as net profit.
Cash quality
1.5×Cash from Edwards Lifesciences Corporation's business was 1.5× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
80.2×Edwards Lifesciences Corporation's operating profit covered its interest costs 80.2 times in the year to Dec 2025.
Cash vs debt
Net cashEdwards Lifesciences Corporation held $3.5 B more cash than debt (net cash) at Dec 2025.
Questions
What is Edwards Lifesciences Corporation's P/E ratio?
Investors pay $53.0 for every $1 of Edwards Lifesciences Corporation's yearly profit, higher than 82% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Edwards Lifesciences Corporation: $51.3 B ÷ $10.6 B (30 Jun 2026) = 4.8.
What is Edwards Lifesciences Corporation's return on equity?
Edwards Lifesciences Corporation earned 9.2% on its shareholders' money over the last year, higher than 83% of Healthcare companies in United States.
How much does Edwards Lifesciences Corporation owe compared with what it owns?
Edwards Lifesciences Corporation owes $0.23 for every $1 it owns (low), lower than 69% of Healthcare companies in United States.
Does Edwards Lifesciences Corporation pay a dividend?
No. Edwards Lifesciences Corporation does not currently pay a dividend.
Is Edwards Lifesciences Corporation's revenue growing?
Revenue rose 12% in the year to Dec 2025, and grew 11% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.